NEW YORK, April 11, 2013 /PRNewswire-iReach/ -- SOTIO a.s, a leader in cell therapy treatments for cancer and autoimmune diseases, has added to their senior leadership team with the addition of Heidi M. Hagen as Chief Operating Officer-US and Head of Global Operations Strategy. As the strategic advisor to SOTIO, Epsen Fuller Group completed the successful placement, which encompassed an exhaustive search of the top operational leaders in biotechnology, and specifically cell manufacturing.
"This role is very narrowly focused on cutting-edge therapies based on activated dendritic cells that trigger the immune system for the treatment of cancer and autoimmune diseases", explained Thomas Fuller , Managing Partner of Epsen Fuller Group and leader on his project.
Ms. Hagen is an expert in dendritic cell manufacturing and autologous operations as evidenced in her most recent role as SVP, Operations at Dendreon. Heidi's achievements there were numerous, including building three state-of-the-art, and very high-performing manufacturing facilities, on budget and on schedule. Heidi was formerly at Immunex Corporation, acquired by Amgen, where she held leadership positions in supply chain, clinical operations, and business strategy. Holding an MBA, an MS in Bioengineering, and a BS in cell and molecular biology, all from the University of Washington, Heidi is a widely-recognized authority on cell manufacturing.
"Sotio is focused on becoming a leader in the field of modern biotechnology therapies and related science," says Mr. Fuller. "We were looking for an individual with the real drive and passion to lead the way in commercializing the science of cell manufacturing, thereby enabling SOTIO to flourish as an innovative and fast-growth organization and reinforce its commitment to connecting patients and science."
SOTIO Group is a biotechnology group developing new therapies based on activated dendritic cells, focusing on the treatment of cancer and autoimmune diseases. Its mission is to develop new medical therapies using SOTIO's proprietary cell-based technologies to treat highly unmet medical conditions using SOTIO's immunotherapy platform. World renowned scientists are working at SOTIO's research facilities in Prague using state-of-the art technologies to understand the role of dendritic cells in the therapeutic activation of the body's immune response. SOTIO plans to start a global pivotal Phase 3 clinical trial which will enroll U.S. as well as E.U. patients under the supervision of FDA and EMA. SOTIO, LLC is an affiliate of SOTIO and is responsible for organizing SOTIO Group's activities in the United States.
About Epsen Fuller Group
New York based Epsen Fuller Group, www.epsenfuller.com, is a Top-20 retained executive search and talent management consulting firm with US offices in New York, New Jersey and San Francisco and offices in major markets and business centers throughout the world, providing instant access to a world-class executive talent pool serving the global economy.
Epsen Fuller Group delivers an integrated suite of talent management solutions throughout four business units focused on the acquisition, assessment, and acceleration of talent. EF|IMD conducts senior executive search, TalentKinect executes mid-management recruitment projects, iDestiny offers a variety of leadership assessment, development, and coaching solutions, while EFAdvisory delivers talent assessment and advisory services to enhance governance best practices in corporate Boards and maximize transaction value for Private Equity Groups. The firm specializes in three industry verticals – consumer, life sciences, and the tech|communications|media sectors - placing top talent in blue-chip client organizations worldwide.
Kate Hassey , Epsen Fuller Group, 2123924842, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
|SOURCE Epsen Fuller Group|
Copyright©2012 PR Newswire.
All rights reserved